Genomic marker better informs treatment choices for CRPC
The CYP1B1*3 genotype is a potential marker for poor prognosis for men with castration resistant prostate cancer who received docetaxel-based therapy. Men carrying the homozygous CYP1B1*3 genotype (o) had reduced survival times compared to patients carrying at least one copy of the unmutated form of the gene (*). Docetaxel remains the frontline standard of care […]